# ![@LTVresearch Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1897419857156558848.png) @LTVresearch LongTermValue Research

LongTermValue Research posts on X about $psix, $prva, $veev, ai the most. They currently have [------] followers and [---] posts still getting attention that total [--] engagements in the last [--] hours.

### Engagements: [--] [#](/creator/twitter::1897419857156558848/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1897419857156558848/c:line/m:interactions.svg)

- [--] Week [--] -51%
- [--] Month [---] -82%
- [--] Months [------] +366%
- [--] Year [-------] -94%

### Mentions: [--] [#](/creator/twitter::1897419857156558848/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1897419857156558848/c:line/m:posts_active.svg)

- [--] Week [--] -22%
- [--] Month [--] -48%
- [--] Months [--] +300%
- [--] Year [---] +11,100%

### Followers: [------] [#](/creator/twitter::1897419857156558848/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1897419857156558848/c:line/m:followers.svg)

- [--] Week [---] no change
- [--] Month [---] no change
- [--] Months [---] +68%

### CreatorRank: undefined [#](/creator/twitter::1897419857156558848/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1897419857156558848/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  [finance](/list/finance)  [cryptocurrencies](/list/cryptocurrencies)  [currencies](/list/currencies)  [countries](/list/countries)  [technology brands](/list/technology-brands)  [financial services](/list/financial-services)  [celebrities](/list/celebrities) 

**Social topic influence**
[$psix](/topic/$psix), [$prva](/topic/$prva), [$veev](/topic/$veev), [ai](/topic/ai), [$2bn](/topic/$2bn), [$hims](/topic/$hims), [$rhm](/topic/$rhm), [growth](/topic/growth), [bullish](/topic/bullish), [eps](/topic/eps)

**Top assets mentioned**
[Privia Health Group, Inc.  (PRVA)](/topic/$prva) [Veeva Systems, Inc. (VEEV)](/topic/$veev) [Hims & Hers Health, Inc. (HIMS)](/topic/$hims) [Danaher Corporation (DHR)](/topic/$dhr) [Sei (SEI)](/topic/$sei) [CatCoin (CAT)](/topic/$cat) [Clearwater Analytics Holdings, Inc. (CWAN)](/topic/$cwan) [Remitly Global, Inc. (RELY)](/topic/$rely) [#MLM (#MLM)](/topic/$mlm) [Cummins Inc. (CMI)](/topic/$cmi) [Generac Holdings Inc. (GNRC)](/topic/$gnrc) [Altria Group Inc (MO)](/topic/$mo) [Common Wealth (WLTH)](/topic/$wlth) [Charles Schwab Corporation (SCHW)](/topic/$schw) [Bull Market (BULL)](/topic/$bull) [NVIDIA Corp. (NVDA)](/topic/$nvda) [Vulcan Materials Company (VMC)](/topic/$vmc) [CRH Public Limited Company (CRH)](/topic/$crh) [Eagle Materials, Inc. (EXP)](/topic/$exp) [Granite Construction Inc. (GVA)](/topic/$gva) [Corteva Inc (CTVA)](/topic/$ctva) [Carvana Co. (CVNA)](/topic/$cvna) [Brookfield Corporation (BN)](/topic/$bn) [4 (FOUR)](/topic/$four) [Evolent Health, Inc Class A Common Stock (EVH)](/topic/$evh)
### Top Social Posts
Top posts by engagements in the last [--] hours

"@R2Discovery @longandquant I think more likely bought by a growth equity firm like TA EQT or Thoma Bravo. Thoma raised a 1.8bn Europe fund in [--] for Euro software. They took EQS (compliance software) private at 400m in [--] was 4x fwrd sales (less growth). 5x takeout = 66% upside for $ALLIX"  
[X Link](https://x.com/LTVresearch/status/1958959065834328168)  2025-08-22T18:26Z [---] followers, [----] engagements


"@blondesnmoney @victaurs $RELY"  
[X Link](https://x.com/LTVresearch/status/1900299971263430952)  2025-03-13T21:36Z [--] followers, [--] engagements


"Thread on $VMC. Vulcan materials is in a 20% drawdown from its 30d high. Mgmt is guiding for 3-5% volume growth + 5-7% pricing growth for [--]. The company recorded double-digit increases in gross profit per ton on aggregates in [--] exiting the year +16% to $11.50 in Q4"  
[X Link](https://x.com/LTVresearch/status/1900315372802253217)  2025-03-13T22:37Z [---] followers, [---] engagements


"With a favorable pricing environment they expect Adj. EBITDA to increase 19% to $2.45bn (midpoint) in [--]. Keep in mind 90% of revenues are tied to markets (southern U.S. with +ve demographic trends) where Vulcan has a #1 or #2 position and projects are typically multi-year"  
[X Link](https://x.com/LTVresearch/status/1900315435376984539)  2025-03-13T22:38Z [--] followers, [--] engagements


"At mp of the guide VMC is trading at 14x EV / EBITDA. A 14% EBITDA growth rate in [--] gets you $2.8bn of EBITDA & a 12.3x mult. Since [----] VMC has traded at an avg of 15.6x EV / NTM EBITDA & a 5.4x turn premium to $MLM $CRH $EXP and $GVA which now trade at 10x EV / NTM"  
[X Link](https://x.com/LTVresearch/status/1900315577513599132)  2025-03-13T22:38Z [--] followers, [--] engagements


"@DannyOcean555 You're on it on the agg mix. $MLM ASPs higher at $21.95 vs $21.08 at #VMC in Q4 '24. VMC mostly South while Marietta has more geo diversity. Definitely a "the margin = opportunity" story: MLM EBITDA margins were 26.5% in '19 vs VMC at 25.8%. In '24 MLM @ 31.6% vs VMC @ 28.8%"  
[X Link](https://x.com/LTVresearch/status/1902010103944921325)  2025-03-18T14:52Z [---] followers, [--] engagements


"@DannyOcean555 Re: '26 est. I'm at $2.78bn / 11% growth from '25. The 14% I used was just the low-end of the '25 guide on top of '25 #s. Broadly should be another year of MSD pricing + 3% volume = +8% rev. Margins are below MLM & I think upside there 40% incrementals seems realistic in '26"  
[X Link](https://x.com/LTVresearch/status/1902021536757825696)  2025-03-18T15:37Z [---] followers, [--] engagements


"Write up summary on $PSIX. Power Solutions is a data center buildout beneficiary trading below 6x [--] P/E. The company makes backup power generators for AI data centers the power segment growing 62% in Q4. Mgmt. has strategically pivoted away from industrial and transportation"  
[X Link](https://x.com/LTVresearch/status/1906806102454419592)  2025-03-31T20:29Z [--] followers, [---] engagements


"New write up on $RHM $RNMBY. Exceptional growth oppty through end of decade with 100% upside as EPS 5x from 25-30. Rev drivers: NATO increasing defense spending as a % of GDP to 3% from 2% defense procurement favoring EU champions re-armament due to geopolitical tensions"  
[X Link](https://x.com/LTVresearch/status/1914113023377101166)  2025-04-21T00:24Z [---] followers, [----] engagements


"$RHM CEO has started repositioning [----] mid-term revenue goals around 40bn (up from 30bn as of Nov. 24). NATO conference in June should serve as a massive catalyst as EU countries near-shore procurement. Company should be a massive beneficiary of rising global tensions"  
[X Link](https://x.com/LTVresearch/status/1914113798819979722)  2025-04-21T00:27Z [--] followers, [---] engagements


"Orders (which translate to backlog) could reach 300bn by end of decade against 12.6bn of sales in 25: providing exceptional visibility and backlog coverage for a defense business. With Electronic Solutions and air defense products providing a backbone for revenue growth"  
[X Link](https://x.com/LTVresearch/status/1914114675148472480)  2025-04-21T00:31Z [--] followers, [--] engagements


"We should expect a 25% revenue growth CAGR which (along with margin expansion) should translate to EPS growth from [--] to [---]. With shares trading at sub 10x [--] EPS $RHM looks like an easy double through [--] and 120% upside at 20x [--] EPS"  
[X Link](https://x.com/LTVresearch/status/1914115383981654386)  2025-04-21T00:34Z [--] followers, [---] engagements


"Ahead of the critical NATO Summit President Trump truthed the below image with sights set on convincing NATO members to increase defense spend to 5% of GDP. We wrote about implications for $RHM (+17% since we posted) in late April. We still see upside amid geopolitical strain. New write up on $RHM $RNMBY. Exceptional growth oppty through end of decade with 100% upside as EPS 5x from 25-30. Rev drivers: NATO increasing defense spending as a % of GDP to 3% from 2% defense procurement favoring EU champions re-armament due to geopolitical tensions https://t.co/Pt5bmN8Zcn New write up on $RHM"  
[X Link](https://x.com/LTVresearch/status/1937533738423910538)  2025-06-24T15:30Z [---] followers, [---] engagements


"@Stock_Pursuit Agree Very compelling at these prices. Easy to see +100% upside from here New idea on a negative EV net-net. Dissimilar from your typical busted biotech net-net this company is growing profitable and repurchasing shares. Multi-bagger potential if the co is acquired by a $100bn mkt cap S&P [---] member that already owns 40% of the shares. Link in bio. https://t.co/xSmCCXRrjn New idea on a negative EV net-net. Dissimilar from your typical busted biotech net-net this company is growing profitable and repurchasing shares. Multi-bagger potential if the co is acquired by a $100bn mkt"  
[X Link](https://x.com/LTVresearch/status/1943141487283441806)  2025-07-10T02:53Z [---] followers, [--] engagements


"@quantian1 Revision lol: *FIGMA SHARES INDICATED TO OPEN AT $97/$100 EACH IPO PRICE $33"  
[X Link](https://x.com/LTVresearch/status/1950968559028547831)  2025-07-31T17:15Z [---] followers, [---] engagements


"As earnings come to a close this week I posted updates for $RELY $PSIX $CRON $CBAV $VLE and $RHM. I left the Remitly review free to all subs the other [--] are behind a paywall. I update on earnings takeaways my positioning and updated valuation and upside thoughts"  
[X Link](https://x.com/LTVresearch/status/1953911164532097078)  2025-08-08T20:08Z [---] followers, [----] engagements


"@rubicon59 The Form [---] they filed is just a proposed sale and indication of an intention to sell. Just 1.06m shares traded between 8/12 and today so cant imagine its been completed. This sale would take Weichai ownership to 46% with 4/7 board seats. Ripe for an activist in my opinion"  
[X Link](https://x.com/LTVresearch/status/1956077193425248553)  2025-08-14T19:35Z [---] followers, [---] engagements


"@rubicon59 @rubicon59 Weichai America Corp performed an open-market sale (S) of 123.8k shares of Power Solutions International (PSIX) on 8/12/25 at an average price of $93.81 per share. I have them now at 50.48% ownership. I actually think going below 50% would be a major positive"  
[X Link](https://x.com/LTVresearch/status/1956109613129969802)  2025-08-14T21:44Z [---] followers, [--] engagements


"Insiders incl. Weichai (51% holder) have been selling shares over the past few days resulting in a substantial disconnect from fundamentals. Weichai is now at 50.5% ownership I view ownership below 50% as a major benefit since norm. holders own more than the Chinese parent"  
[X Link](https://x.com/LTVresearch/status/1956115172805775623)  2025-08-14T22:06Z [---] followers, [----] engagements


"Looking at peer Q2 industrial / power segment sales $SEI was +53% $CMI +19% $CAT +7% and $GNRC +5%. $PSIX was +115% and is obviously winning significant share. I expect 85% growth in this segment this year with 25% next year. Gross margins could also increase as they ramp up"  
[X Link](https://x.com/LTVresearch/status/1956116650568405401)  2025-08-14T22:12Z [---] followers, [----] engagements


"The company has just $46m (0.3x net leverage) of net debt and the Weichai shareholder loan has been replaced with a new [----] credit agreement. The company should have a net cash balance by YE [--] making for a clean balance sheet and potentially cleaned up shareholder base"  
[X Link](https://x.com/LTVresearch/status/1956117546538557486)  2025-08-14T22:15Z [---] followers, [---] engagements


"@ValueInvest2020 Agree. We probably get selling through Thursday or Friday. Think it makes sense to add below $80. Becoming pretty dislocated from fair value"  
[X Link](https://x.com/LTVresearch/status/1957910155963904109)  2025-08-19T20:58Z [---] followers, [---] engagements


"Today was a [--] sigma move in the MS Momentum index (3.86%) since [----]. Weve seen only 2.9% of days with worse momentum factor performance over that period"  
[X Link](https://x.com/LTVresearch/status/1957918062138782111)  2025-08-19T21:30Z [---] followers, [---] engagements


"@anonymouskeepit Another 125k today think they are done by Friday at this rate with 487k to go. Yes they may have given Goldman directions to only sell above $80 which is why these sales have been so poorly executed"  
[X Link](https://x.com/LTVresearch/status/1958263651183341701)  2025-08-20T20:23Z [---] followers, [---] engagements


"@CFAs4CFPs Positive outcome. Will take some time to worth through the full claims. Per BBG looks like $390m: Delek's 2021-22 SRE grants carried a value of roughly $780m at weighted-average prices. Its 23-24 grants may result in legacy vintage RINs valued at $390m at current prices"  
[X Link](https://x.com/LTVresearch/status/1960055189555323226)  2025-08-25T19:02Z [---] followers, [--] engagements


"@blondesnmoney Breaking: Citi sales team spotted walking the runway at a NYFW event. More updates to follow"  
[X Link](https://x.com/LTVresearch/status/1966556236498772324)  2025-09-12T17:35Z [---] followers, [---] engagements


"Corteva $CTVA is pretty interesting here. Supplier of seeds and crop protection exploring a breakup per WSJ. Q2 [--] EPS exceeded expects in both seed & crop protection segments due to pricing volume & margin. Co raised EPS guidance from $2.70-2.95 to $3.00-3.20 for 25"  
[X Link](https://x.com/LTVresearch/status/1966596447006040327)  2025-09-12T20:15Z [---] followers, [---] engagements


"Benefited from strong seed pricing market share gains and commodity cost deflation. Its a 7-9% organic HSD grower with margin expansion getting them to 21% EPS growth at midpoint. Can do another high teens EPS % growth in [--] to get to $3.70 = 20x [--] EPS at $74"  
[X Link](https://x.com/LTVresearch/status/1966596699725410428)  2025-09-12T20:16Z [---] followers, [---] engagements


"Since we recommended $PSIX below $80 a month ago due to technical selling equity is up more than 35%. Cheers to all that followed. We still see fair value closer to $140 & view $PSIX as the cheapest data center power beneficiary at 13x [--] P/E while growing top line 57% in [--] Weichai sold another 136k shares on 8/14. Takes their stake to 49.2%. Assuming similar sales on Friday and today (makes sense w/ this AMs price action) selling should be done on the full 1.15m sale by Thurs. $PSIX is really attractive below $80 on this technical pressure. Weichai sold another 136k shares on 8/14. Takes"  
[X Link](https://x.com/LTVresearch/status/1969093035028877786)  2025-09-19T17:35Z [---] followers, [----] engagements


"$MO could pay a very reasonable 10x [----] EBITDA (no synergies) for the 59% they do not own due the large $CRON cash balance. Equates to a 75% premium over the current price at $5.25. Comps with MSD growth trade at 10-18.5x [--] EBITDA while $CRON is growing mid-teens plus"  
[X Link](https://x.com/LTVresearch/status/1972758345456239089)  2025-09-29T20:20Z [---] followers, [---] engagements


"@blondesnmoney Act Now You can still buy $CVNA at the cheap price of 50x [----] FCF with 100% of FCF attributable to loan financings If I had a consumer exposed book Id short the absolute hell out of $CVNA to hedge out my exposure"  
[X Link](https://x.com/LTVresearch/status/1973048436497817816)  2025-09-30T15:32Z [---] followers, [----] engagements


"@rubicon59 @ValueInvest2020 Have done a good amount of work on $SEI and owned it. Need to look at [----] and beyond which is when their JV with Elon (Grok) is fully scaled at their Memphis location. Actually a pretty good $PSIX comp $PSIX just much more attractively priced"  
[X Link](https://x.com/LTVresearch/status/1973136245577621550)  2025-09-30T21:21Z [---] followers, [--] engagements


"In a month the compounder bros are going to throw a party when $DHR is up another 10-20%. Can already see a flood of posts on DBS Kaizen and the hist. value creation. Pfizer deal seems very bullish for domestic bio processingpicked up some shares credible path to $250 by YE"  
[X Link](https://x.com/LTVresearch/status/1973428194582864004)  2025-10-01T16:42Z [---] followers, [--] engagements


"Quick math: $DHR at $7.77 EPS in [--]. Grow at 13% (in line w/ [----] cycle CAGR) $8.78 EPS in [--]. HSD top-line low teens EPS. Slap 28.5x on that and youre at $250. Historic range: 26.5x avg NTM peaks 35x. Risk/reward skews cleanly up. Can easily see $265 on better trends"  
[X Link](https://x.com/LTVresearch/status/1973434694172819837)  2025-10-01T17:07Z [---] followers, [---] engagements


"@TippiYogi No push back here $DHR is a beast gushes cash. Imagine theyll do multi $bn add-ons in BioP & Life Sci over the N24mo while keeping leverage 2.0x net. Easy to see top line growing 10-12% with the inorganic and EPS into teens. Wouldnt be surprised with $15 of EPS in 2030"  
[X Link](https://x.com/LTVresearch/status/1973801698226262406)  2025-10-02T17:26Z [---] followers, [---] engagements


"@bizalmanac @bizalmanac I just (unfortunately) sold $FOUR and hit my stop loss. Hate trading that way bc I believe in management heavilybut adding debt into a potential massive slow down when you are in hyper cyclical industries is troublesome. Welcome any pushback want to re-enter lower"  
[X Link](https://x.com/LTVresearch/status/1974629968069238887)  2025-10-05T00:17Z [---] followers, [---] engagements


"First post of '26. (preview with paywall) $VEEV is a high quality VMS compounder in a 25% drawdown on competitive fears in 20% of the biz. Revenue growth is durable in our view & FCF margins are exceptional @ 40%. New AI product launches should re-rate the equity in '26"  
[X Link](https://x.com/anyuser/status/2008173020590776456)  2026-01-05T13:45Z [---] followers, [----] engagements


"https://open.substack.com/pub/ltvresearch/p/veeva-systems-opportunistic-compounderr=12ud39&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true https://open.substack.com/pub/ltvresearch/p/veeva-systems-opportunistic-compounderr=12ud39&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true"  
[X Link](https://x.com/LTVresearch/status/2008173073590350219)  2026-01-05T13:45Z [---] followers, [---] engagements


"New posted idea in the usual place. Exceptionally mispriced asset trading at 1.0x mid-cycle EBITDA if you short out the listed subsidiary. Pending EPA claim could be worth 3x current stub EV with signs pointing to an imminent decision. I see 70% - 135% upside over 18mo"  
[X Link](https://x.com/LTVresearch/status/1958288589923750136)  2025-08-20T22:02Z [---] followers, [---] engagements


"$PRVA just posted one of the cleanest beat-and-raise quarters in HC. Practice collections +27% y/y adj. EBITDA +62% y/y @ 30.5% (+720bps). Real op leverage and execution from scale + discipline Flywheel working extremely well looks like a compounder with years of runway"  
[X Link](https://x.com/LTVresearch/status/1986444771347280301)  2025-11-06T14:45Z [---] followers, [---] engagements


"80% of EBITDA converts to FCF with no debt and $400M cash. Very rare capital light platform in healthcare services growth is now entirely self-funded and more accretive M&A is on the horizon as they monetize the B/S. $EVH ACO deal adds 120k lives next year w added states"  
[X Link](https://x.com/LTVresearch/status/1986445286282305895)  2025-11-06T14:47Z [---] followers, [---] engagements


"Growth runway is extended through [----] in my view and not being driven by chasing risky MA capitation. Core engine is still provider onboarding + MSSP shared savings + diversified commercial biz. $PRVA has a repeatable scale-driven earnings model"  
[X Link](https://x.com/LTVresearch/status/1986445870355624389)  2025-11-06T14:49Z [---] followers, [---] engagements


"At $26 mkt still prices $PRVA like a low-margin roll-upif execution continues (org EBITDA growth guide is 20%) a high $30s valuation is supported on [--] / [--] numbers. Setup is very strong they can do more M&A and it increasingly looks like a capital light takeout candidate"  
[X Link](https://x.com/LTVresearch/status/1986446503959769363)  2025-11-06T14:52Z [---] followers, [---] engagements


"New post in the normal spot on a small-cap healthcare compounder: $PRVA Asset-light physician enablement platform no clinic capex multi-payer and a net-cash balance sheet. I think this can compound FCF per share 20% with a credible path to 70%+ upside https://open.substack.com/pub/ltvresearch/p/new-idea-healthcare-compounder-withr=12ud39&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true https://open.substack.com/pub/ltvresearch/p/new-idea-healthcare-compounder-withr=12ud39&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true"  
[X Link](https://x.com/anyuser/status/1996581191370092637)  2025-12-04T14:03Z [---] followers, [---] engagements


"$PRVA doesnt buy practices or build boxes. So no insurance alphabet soup. It wraps a tech + services stack around independent physicians: Single-TIN medical groups + ACOs 5k implemented providers 1.4m attributed lives in just [--] states Multi-payer (commercial MA MSSP MDCD)"  
[X Link](https://x.com/LTVresearch/status/1996581558824693987)  2025-12-04T14:05Z [---] followers, [---] engagements


"Anyone know whats going on with this Wealthfront $WLTH IPO IPO range $12-$14 Selling shares @ $14 Indicates to open $15.5 [--] hours ago Now open indicated at $13 Its a +$18 stock if it trades at 12.5x [--] EBITDA vs $SCHW at 13.6x and $BULL at 11.6x. Decent 1yr R/R from $13"  
[X Link](https://x.com/anyuser/status/1999537980902342951)  2025-12-12T17:52Z [---] followers, [----] engagements


"CMS unveiled the new LEAD model a decade-long voluntary program that runs 1/1/27-12/31/36 and is a successor to ACO Reach. I see this as very bullish for VBC and specifically for a platform like $PRVA which provides the tech data and admin backbone for physicians. Heres why:"  
[X Link](https://x.com/anyuser/status/2001775323868745849)  2025-12-18T22:03Z [---] followers, [---] engagements


"Longevity and Visibility: CMS models are typically 3-5 years. A 10-year performance period is unprecedented and significantly extends the visibility of Privias earnings allowing the company to make long-term capital investments in clinical infrastructure"  
[X Link](https://x.com/LTVresearch/status/2001775654690525380)  2025-12-18T22:04Z [---] followers, [--] engagements


"Fixing the "Success Tax": A major risk to MSSP was that more efficient ACOs were rebased lower by CMS making it harder to earn shared savings the following year. LEAD allows superb ACOs like $PRVA to capture the delta for longer protecting the durability of the margin profile"  
[X Link](https://x.com/LTVresearch/status/2001776420066820326)  2025-12-18T22:07Z [---] followers, [--] engagements


"Improved Cash Flow (Capitated Payments): LEAD shifts toward prospective capitated payments for primary care. This is a massive benefit for Privias business model. It moves them away from the "lumpy" annual shared-savings checks and toward predictable monthly revenue stream"  
[X Link](https://x.com/anyuser/status/2001776701823455533)  2025-12-18T22:08Z [---] followers, [---] engagements


"TAM Expansion (Specialists): By integrating Medicaid and creating "CMS Administered Risk Arrangements" (CARA) for specialists LEAD expands the $PRVA TAM. Privia has historically been primary-care heavy; LEAD provides a structured pathway to take risk on specialty episodes"  
[X Link](https://x.com/anyuser/status/2001777008943026282)  2025-12-18T22:10Z [---] followers, [---] engagements


"$VEEV announced a $2bn (6% of mkt cap) share buyback AMC. Stock reacting positively +1.4% as board agrees with me that equity is undervalued Lucky timing on the post this morning"  
[X Link](https://x.com/anyuser/status/2008293999207973318)  2026-01-05T21:46Z [---] followers, [---] engagements


"$VEEV is +12% from $218 - $244 since we posted [--] days ago. Just made the full (paid) post free for all subscribers. Think there is a lot of re-rating to historic multiples left as the competitive narrative stabilizes. The new $2bn buyback helps too https://open.substack.com/pub/ltvresearch/p/veeva-systems-opportunistic-compounderr=12ud39&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true https://open.substack.com/pub/ltvresearch/p/veeva-systems-opportunistic-compounderr=12ud39&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true"  
[X Link](https://x.com/anyuser/status/2009476176079986944)  2026-01-09T04:03Z [---] followers, [---] engagements


"Link in bio for my write-up on $CBAV. I view this as one of the most attractive & mispriced securities in the market. Has grown EBITDA 20% each of the last [--] years ROIC 30% and trades at sub 8x EBITDA with a 11% FCF yield. Float dynamics are improving and I see 100% upside"  
[X Link](https://x.com/LTVresearch/status/1930733843012628984)  2025-06-05T21:09Z [---] followers, [----] engagements


"@R2Discovery @R2Discovery seems we fish in a number of the same ponds (Wallix Rheinmetall). Curious on your thoughts on margins by biz type for $SJJ. $NOW in the 80s on GMs and 35% on EBITDA. Maybe $SJJ is 25% EBITDA margin when scaled and thus trades 5.3x fwrd EBITDA at 25% mid-term margin"  
[X Link](https://x.com/LTVresearch/status/1958977136012009983)  2025-08-22T19:38Z [---] followers, [---] engagements


"$CRON We are +60% since recommending the equity at a negative EV. It was a sleep well at night pitch in June and is now an asymmetric play on legalization. I would not rule out a takeout from $MO which owns 41% of the equity already and could easily pay 100% above current prices New idea on a negative EV net-net. Dissimilar from your typical busted biotech net-net this company is growing profitable and repurchasing shares. Multi-bagger potential if the co is acquired by a $100bn mkt cap S&P [---] member that already owns 40% of the shares. Link in bio. https://t.co/xSmCCXRrjn New idea on a"  
[X Link](https://x.com/LTVresearch/status/1972755047814684864)  2025-09-29T20:07Z [---] followers, [---] engagements


"$PSIX looking attractive again $100. Base case est. of $6.60 / $8.50 of EPS in '26 / '27 peers trade at 21.5x '26x & 16x '27 PE. Company should be debt free by YE and start to pile up cash on the B/S thru '26. Easy 50% upside as equity reprices to '27. Charts from BCA"  
[X Link](https://x.com/LTVresearch/status/1973080570197377421)  2025-09-30T17:40Z [---] followers, [----] engagements


"@ValueInvest2020 @rubicon59 $SEI $GNRC (agree much less lower AI exposure) $CMI $CAT. The more pure play AI companies trade at 30x [--] and 24x [--]. I dont feel its completely fair to comp to them given that $PSIX is definitely benefitting from a point in time in the supply/demand imbalance"  
[X Link](https://x.com/LTVresearch/status/1973105621172933044)  2025-09-30T19:20Z [---] followers, [---] engagements


"$DHR setting up for a compounder bro victory lap. Add another +15% and well be drowning in DBS/Kaizen/historical value creation posts. Pfizer deal is a big win for domestic bioprocessing and I expect more deals to come. Picked up some shares. $250 by YE feels very doable"  
[X Link](https://x.com/LTVresearch/status/1973434185676366321)  2025-10-01T17:05Z [---] followers, [---] engagements


"@blondesnmoney @blondesnmoney $CCCXW warrants offer more convexity. Red. rights @ $18 but you get a little extra asymmetric juice if trades anything like the other quantum names. I dont understand the whole space but do like making money & from Infleqtion tech is the most real of all of them"  
[X Link](https://x.com/LTVresearch/status/1975368963275301111)  2025-10-07T01:13Z [---] followers, [---] engagements


"@TheIcahnist @OrlandoBravoTB @R2Discovery check out 8:25 when Orlando starts talking about AI tailwinds for cyber. And European firms are just going to opt for US cyber security firms defending against AI threats and not an onshore player like $ALLIX So bullish"  
[X Link](https://x.com/LTVresearch/status/1976016475464008096)  2025-10-08T20:06Z [---] followers, [----] engagements


"1/n $HIMS women's health launch is actually compelling. Company launches into 1-2 new verticals / yr w/ a credible history of product led growth & an emphasis on personalized healthcare. Pen to paper on verticals (ests) below.guide of $6.5bn topline by [----] including inorganic"  
[X Link](https://x.com/LTVresearch/status/1978900380592284137)  2025-10-16T19:06Z [---] followers, [----] engagements


"If ests are correct and inorganic rev is thoughtful (I model rev multiples in line w/ the recent Zava-Europe deal) can pencil to $1.3bn of EBITDA (20% margin guide) by '30. @ 75% FCF conv looking at $3.40 of FCF / sh. Growth HC should trade at 30x FCF good for 74% upside"  
[X Link](https://x.com/LTVresearch/status/1978902260185751832)  2025-10-16T19:13Z [---] followers, [---] engagements


"I know $HIMS is a retail favorite and the recent credit card data has been weak(ish) but there's real upside from these prices on the back of the Menopause launch. You could make a pretty decent 12.5% IRR through [----] if you can stomach the volatility and be disciplined on R/R"  
[X Link](https://x.com/LTVresearch/status/1978902679888814485)  2025-10-16T19:15Z [---] followers, [---] engagements


"1/n Numbers below illustrate a bear case for $HIMS: GLP-1 price caps hit in [----] $HIMS loses share to Novo and Lilly as their drugs are priced $150-$200. Canada GLP-1s go generic. Hormone revenues (read HERS) grow modestly. New verticals roll out in 26-29 but traction is muted"  
[X Link](https://x.com/LTVresearch/status/1979257268601287047)  2025-10-17T18:44Z [---] followers, [---] engagements


"Growth stalls in '27 before reaccelerating to 15% from '28-'30. In this setup $HIMS can still reach $4.15B revenue and $750M EBITDA (18% margin) by [----] driving $560M FCF (75% conversion). That's $2.05 FCF / share. I think this is exactly what the market is digesting today"  
[X Link](https://x.com/LTVresearch/status/1979257542887784631)  2025-10-17T18:45Z [---] followers, [---] engagements


"Per Bloomberg on GLP-1s @ $150 /mo implementation would be challenging especially as there's no detail on the proportion of patients the lower price would actually apply to. As such we view $NVO & $LLY negative share price moves as knee-jerk reactions $HIMS too I would add"  
[X Link](https://x.com/LTVresearch/status/1979293956551639230)  2025-10-17T21:10Z [---] followers, [---] engagements


"Recent ERCOT pres on grid planning. Specific wording around "bringing own generation" is bullish for $PSIX and the on-site generation & backup power narrative. Equity looks exceptionally attractive: on $8.50 of '27 of EPS there's 80% upside if it trades close to peers (14-20x)"  
[X Link](https://x.com/LTVresearch/status/1980638849673097691)  2025-10-21T14:14Z [---] followers, [----] engagements


"@TheLAPurchaser $150 is classic art of the deal nonsense imho. Not to mention would send a terrible signal on drug pricing for every biotech needing to spend multiple $100m to get FDA approved. Couldnt a $HIMS cut prices at expense of GMs Even at $300 for GLP-1s compounded drugs are value It looks like $NVO's COGS / monthly GLP-1 injection is 7% ( not disclosed).this tracks to 62% gross margins at $HIMS (not disclosed). If Ozempic (and the other GLP-1s) have to cut the price to $150 then GMs = 50%. $HIMS could cut to price to $125 from $199 and earn 40% GMs https://t.co/xtgcz02l4O It looks"  
[X Link](https://x.com/LTVresearch/status/1980824862575956326)  2025-10-22T02:33Z [---] followers, [---] engagements


"$PSIX Details emerge on $ORCL and OpenAIs 2nd Stargate data center. Will be a 700MW microgrid powered by an off grid natural gas microgrid. [---] industrial gas generators & [--] engines will be used for backup energy in emergency situations Very bullish https://www.businessinsider.com/openai-building-natural-gas-microgrid-at-new-texas-data-center-2025-10 https://www.businessinsider.com/openai-building-natural-gas-microgrid-at-new-texas-data-center-2025-10"  
[X Link](https://x.com/LTVresearch/status/1981417794001342965)  2025-10-23T17:49Z [---] followers, [----] engagements


"@jb_equities We are long fundamentals and the market is short patience $PSIX looks extremely cheap for the growth profile. Pretty crazy to me we get to buy this at 12x forward P/E again"  
[X Link](https://x.com/LTVresearch/status/1982863764040061338)  2025-10-27T17:35Z [---] followers, [---] engagements


"$PSIX almost a pure play data center backup power generator company up only 7% vs $CAT +13% after Caterpillars Energy & Transportation unit sales were +17% as demand for power gen equip pushed backlog to a record $39.8bn. $PSIX has Q2 rev growth in their power unit of 115%"  
[X Link](https://x.com/LTVresearch/status/1983551438123905427)  2025-10-29T15:08Z [---] followers, [----] engagements


"@blondesnmoney @blondesnmoney Little alpha tip on this one. They have a private earnings call at 3pm ET if you email IR. Imagine they got a ton of angry emails about the limited guide clarity and overall lack of IR function"  
[X Link](https://x.com/LTVresearch/status/1987914778648469982)  2025-11-10T16:06Z [---] followers, [---] engagements


"@NicoCorona17 Quarter was ok not great. Lowest EBITDA margin in 18mo is disappointing vs the market backdrop. They should be earning excess margins not declining. Its a 4% FCF margin biz now anticipating a massive growth deceleration in Q4. I thought the call with Dino today was not good"  
[X Link](https://x.com/LTVresearch/status/1987992771136024875)  2025-11-10T21:16Z [---] followers, [--] engagements


"@jim_jones69 @ValueInvest2020 @rubicon59 @SimeonResearch_ Blogs of hyper growth the past [--] quarters seem to be from a hyper scaler"  
[X Link](https://x.com/LTVresearch/status/1988005919599259984)  2025-11-10T22:08Z [---] followers, [---] engagements


"$NVDA All of these accounts griping about AR increase obviously have never found accounting shorts. AR q/q was +20% and revenue was +22%. Even more: AR / quarterly revenue was 58.6% vs 59.5% last Q. Not channel stuffing not problematic not revenue pull forward. 1/2"  
[X Link](https://x.com/LTVresearch/status/1991354388271817093)  2025-11-20T03:54Z [---] followers, [---] engagements


"This would be a yellow flag if AR growth rev growth but it simply isnt. Focus on whether or not $NVDA is overearning not nitpick accounting. Growth is superb margins are insane and the thing gushes cash. Discl: no position"  
[X Link](https://x.com/LTVresearch/status/1991354652500324542)  2025-11-20T03:55Z [---] followers, [---] engagements


"The moat is switching costs + local network density with bargaining power vs payers. At $2.7bn EV you get: 2025E: $120m EBITDA 80% FCF conv 2028E: $225250m EBITDA low/mid-30s% margin 17x [--] EBITDA 20x [--] FCF 11x 2028E EBITDA for a capital-light net-cash platform"  
[X Link](https://x.com/LTVresearch/status/1996581995116114241)  2025-12-04T14:06Z [---] followers, [--] engagements


"Linked post dives into the full thesis: Business + industry structure Unit economics Moat risks & regulatory map Bear / base / bull w/ EBITDA FCF and IRR math Buyside level price target Its a solid name for investors looking to avoid AI noise and buy defensive compounders"  
[X Link](https://x.com/anyuser/status/1996582476647420149)  2025-12-04T14:08Z [---] followers, [---] engagements


"We went long $CWAN at $20.4 entry on 11/17. We believed the takeout rumors were real and LBO math makes sense. Nice +20% in a month. Now focus shifts to whether Starboard will push board to shop it (we think 50% chance) or if Thoma will come in and top it (20% chance). Cheers"  
[X Link](https://x.com/anyuser/status/2002861383525007400)  2025-12-21T21:58Z [---] followers, [---] engagements


"@negligible_cap $0.40 offer spread as of this AM 3.6% implied IRR to end of 1H close. Market telling me very high probability of deal close. Maybe 20-50% chance of a better offer. Imagine Starboard is working the board right now to get them to actually shop it over the next month"  
[X Link](https://x.com/LTVresearch/status/2003104931700789470)  2025-12-22T14:06Z [---] followers, [--] engagements


"@negligible_cap $0.40 offer spread as of this AM 3.6% implied IRR to end of 1H close. Market telling me very high probability of deal close. Maybe 20-50% chance of a better offer. Imagine Starboard is working the $CWAN board right now to get them to actually shop it over the next month"  
[X Link](https://x.com/LTVresearch/status/2003105910823297356)  2025-12-22T14:10Z [---] followers, [---] engagements


"@rubicon59 $FTAI announcing entry into the market (copy cat competitive move of the private co Superpower) with aircraft engines being converted into gas turbines seems to be the major culprit of the $PSIX move. Still think they do $6 of EPS in [--] and $8 in [--]. Super cheap sub 9x / 7x"  
[X Link](https://x.com/LTVresearch/status/2006449708630512110)  2025-12-31T19:37Z [---] followers, [---] engagements


"Bingo $VEEV +5% on the back of the $2bn share repurchase last night. Noted visibility into growth runway in the PR. Seems they agree with me that the equity is very undervalued"  
[X Link](https://x.com/anyuser/status/2008549164372947322)  2026-01-06T14:40Z [---] followers, [---] engagements


"@TheLAPurchaser @AIStockSavvy @borrowed_ideas @invest091 @7Innovator @Kaizen_Investor @GilesCapital @joinyellowbrick"  
[X Link](https://x.com/anyuser/status/2009477858427895988)  2026-01-09T04:10Z [---] followers, [---] engagements


"🦔 The EU is considering deploying its "Anti-Coercion Instrument" against the U.S. for the first time ever. This comes after Trump announced tariffs on eight European countries starting at 10% on Feb. [--] and rising to 25% by June [--] unless they agree to let the U.S. acquire Greenland. The targeted countries: Denmark Norway Sweden France Germany the U.K. the Netherlands and Finland. These would stack on top of existing tariffs already at 10-15%. The ACI is considered the EU's nuclear option. It could restrict U.S. suppliers from EU markets block them from public contracts impose export and"  
[X Link](https://x.com/anyuser/status/2013360864884093176)  2026-01-19T21:20Z 28.6K followers, 10.9K engagements


"$VEEV is +12% from $218 - $244 since we posted [--] days ago. Just made the full (paid) post free for all subscribers. Think there is a lot of re-rating to historic multiples left as the competitive narrative stabilizes. The new $2bn buyback helps too https://open.substack.com/pub/ltvresearch/p/veeva-systems-opportunistic-compounderr=12ud39&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true https://open.substack.com/pub/ltvresearch/p/veeva-systems-opportunistic-compounderr=12ud39&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true"  
[X Link](https://x.com/anyuser/status/2009476176079986944)  2026-01-09T04:03Z [---] followers, [---] engagements


"@TheLAPurchaser @AIStockSavvy @borrowed_ideas @invest091 @7Innovator @Kaizen_Investor @GilesCapital @joinyellowbrick"  
[X Link](https://x.com/anyuser/status/2009477858427895988)  2026-01-09T04:10Z [---] followers, [---] engagements


"First post of '26. (preview with paywall) $VEEV is a high quality VMS compounder in a 25% drawdown on competitive fears in 20% of the biz. Revenue growth is durable in our view & FCF margins are exceptional @ 40%. New AI product launches should re-rate the equity in '26"  
[X Link](https://x.com/anyuser/status/2008173020590776456)  2026-01-05T13:45Z [---] followers, [----] engagements


"Bingo $VEEV +5% on the back of the $2bn share repurchase last night. Noted visibility into growth runway in the PR. Seems they agree with me that the equity is very undervalued"  
[X Link](https://x.com/anyuser/status/2008549164372947322)  2026-01-06T14:40Z [---] followers, [---] engagements


"$VEEV announced a $2bn (6% of mkt cap) share buyback AMC. Stock reacting positively +1.4% as board agrees with me that equity is undervalued Lucky timing on the post this morning"  
[X Link](https://x.com/anyuser/status/2008293999207973318)  2026-01-05T21:46Z [---] followers, [---] engagements


"https://open.substack.com/pub/ltvresearch/p/veeva-systems-opportunistic-compounderr=12ud39&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true https://open.substack.com/pub/ltvresearch/p/veeva-systems-opportunistic-compounderr=12ud39&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true"  
[X Link](https://x.com/LTVresearch/status/2008173073590350219)  2026-01-05T13:45Z [---] followers, [---] engagements


"We went long $CWAN at $20.4 entry on 11/17. We believed the takeout rumors were real and LBO math makes sense. Nice +20% in a month. Now focus shifts to whether Starboard will push board to shop it (we think 50% chance) or if Thoma will come in and top it (20% chance). Cheers"  
[X Link](https://x.com/anyuser/status/2002861383525007400)  2025-12-21T21:58Z [---] followers, [---] engagements


"@smantel @TheAroraReport @TheBenSchmark @negligible_cap"  
[X Link](https://x.com/anyuser/status/2002862187489231208)  2025-12-21T22:02Z [---] followers, [---] engagements


"CMS unveiled the new LEAD model a decade-long voluntary program that runs 1/1/27-12/31/36 and is a successor to ACO Reach. I see this as very bullish for VBC and specifically for a platform like $PRVA which provides the tech data and admin backbone for physicians. Heres why:"  
[X Link](https://x.com/anyuser/status/2001775323868745849)  2025-12-18T22:03Z [---] followers, [---] engagements


"Improved Cash Flow (Capitated Payments): LEAD shifts toward prospective capitated payments for primary care. This is a massive benefit for Privias business model. It moves them away from the "lumpy" annual shared-savings checks and toward predictable monthly revenue stream"  
[X Link](https://x.com/anyuser/status/2001776701823455533)  2025-12-18T22:08Z [---] followers, [---] engagements


"TAM Expansion (Specialists): By integrating Medicaid and creating "CMS Administered Risk Arrangements" (CARA) for specialists LEAD expands the $PRVA TAM. Privia has historically been primary-care heavy; LEAD provides a structured pathway to take risk on specialty episodes"  
[X Link](https://x.com/anyuser/status/2001777008943026282)  2025-12-18T22:10Z [---] followers, [---] engagements


"Anyone know whats going on with this Wealthfront $WLTH IPO IPO range $12-$14 Selling shares @ $14 Indicates to open $15.5 [--] hours ago Now open indicated at $13 Its a +$18 stock if it trades at 12.5x [--] EBITDA vs $SCHW at 13.6x and $BULL at 11.6x. Decent 1yr R/R from $13"  
[X Link](https://x.com/anyuser/status/1999537980902342951)  2025-12-12T17:52Z [---] followers, [----] engagements


"New post in the normal spot on a small-cap healthcare compounder: $PRVA Asset-light physician enablement platform no clinic capex multi-payer and a net-cash balance sheet. I think this can compound FCF per share 20% with a credible path to 70%+ upside https://open.substack.com/pub/ltvresearch/p/new-idea-healthcare-compounder-withr=12ud39&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true https://open.substack.com/pub/ltvresearch/p/new-idea-healthcare-compounder-withr=12ud39&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true"  
[X Link](https://x.com/anyuser/status/1996581191370092637)  2025-12-04T14:03Z [---] followers, [---] engagements


"Linked post dives into the full thesis: Business + industry structure Unit economics Moat risks & regulatory map Bear / base / bull w/ EBITDA FCF and IRR math Buyside level price target Its a solid name for investors looking to avoid AI noise and buy defensive compounders"  
[X Link](https://x.com/anyuser/status/1996582476647420149)  2025-12-04T14:08Z [---] followers, [---] engagements


"@joinyellowbrick @StockCompil @GilesCapital @MaheshJagadish @lite__spectre @VagabondRTW @aEcxnUcrqsh5mqD @nlelandw @TheLAPurchaser @systematicEDGE @marc_slans"  
[X Link](https://x.com/anyuser/status/1996606781259186288)  2025-12-04T15:45Z [---] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing